Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Outlook
2023

Annual Industry Ranking And Forecast

VIEW NOW

Featured Stories


J&J Quits RSV Development With Two Rivals Already Poised For US Approval

The pharma, which has been de-emphasizing vaccines and infectious disease of late, will end its Phase III trial for an RSV vaccine with May approvals pending for both Pfizer’s and GSK’s candidates.

Business Strategies Clinical Trials Vaccines

Wegovy CVOT Data Could Pave The Way For Broad Reimbursement, CEO Says

Novo Nordisk CEO Lars Jørgensen discussed the supply and market access position of its rising obesity drug, Wegovy, during the CNBC Health Returns conference.

Metabolic Disorders Reimbursement Market Access

Scrip Asks…What Does 2023 Hold For Biopharma? Part 10: Diversity, Equity And Inclusion

The acceleration of efforts to increase diversity among clinical trial subjects is expected to continue in 2023. Furthermore, many executives hope for greater inclusivity within companies, from new recruits to leadership.

Scrip Asks Diversity & Inclusion Leadership

Asia Spotlight

As Japan’s Syphilis Cases Surge, So Do Calls For More Therapeutics

As Japan faces skyrocketing syphilis cases, hopes have been high among domestic physicians for a single-dose therapeutic in the form of benzylpenicillin injection. But the country has approved the drug only recently and in answer to a push from doctors on the front line.

Japan Infectious Diseases

More coverage from Scrip's team in Asia

Latest News

Scrip Podcast

Insights and perspectives on commercial, R&D, deal-making and business strategy developments.

MORE PODCASTS

 

Infographics

India M&As Overtook PE Activity In 2022, Deal Momentum To Continue In 2023

India had a busy deals calendar in 2022, with companies led by Biocon striking large M&A deals while PE activity declined. Scrip pieced together data for infographics on these deals. A multitude of factors is expected to keep the momentum going in 2023

Commercial Scrip Perspectives

The Deal Landscape At Mid-Year: Is Industry Following Through On Business Development Promises?

INFOGRAPHIC: Going into 2022, there were high expectations for deal-making, but industry continues to face significant headwinds. Scrip reviewed M&A and alliance activity for the first half of the year to track how business development is shaping up in 2022. 

Deals M & A

Titans Of Pharma 2022: Johnson & Johnson Pays Highest Exec Compensation Again

Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.

Companies Leadership

Commercial Explore this Topic

Set Alert for Commercial

Latest From Commercial

First Drugs That Could Be Picked For Price Negotiation Showcase Longevity Of Some Brands

The first drugs expected to face US Medicare drug price negotiations, according to a new analysis, will have had an average commercial life span of 15 years.

Medicare Reimbursement

Investors Take Flight After Bluebird Bio’s Sickle Cell Delay

Bluebird’s first two gene therapies are on the market, but a new delay to its biggest hope, the sickle cell disease candidate lovo-cell, has spooked investors.

Blood & Coagulation Disorders Gene Therapy

Roche Continues To Cast Its Collaborations Net Wide

The Swiss major gets around 3,000 proposals per year and has assembled a 120-strong team to sift through them and access the best science out there. Global head of pharma partnering James Sabry tells Scrip what Roche is looking for in a partner.

Deals Business Strategies

Boehringer To Profit From Jardiance Well Into Second Half Of Decade

The German firm is anticipating a major label expansion in kidney disease for its SGL2 inhibitor later this year, prompting Boehringer to gear up commercial activities as AstraZeneca’s rival Farxiga faces the threat of generic competition.

Sales & Earnings Renal

Ransomware Attacks: The State Of Play As Indian Firms Mount Defense

Pharma continues to be targeted by cyber criminals – the latest being India’s top-ranked company, Sun Pharma. Experts highlight some of the key vulnerabilities and why firms need to prioritize cyber resilience.

Commercial Cybersecurity

Celltrion Eyes M&A, Global Expansion And Novel Drugs As Founder Returns

Celltrion founder and chairman Jung Jin Seo has outlined why he has decided to return to the Korean biosimilars major and the business priorities for the group if it is to emerge as a top-tier global biopharma operation.

Business Strategies South Korea
See All

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

Latest From Policy & Regulation

First Drugs That Could Be Picked For Price Negotiation Showcase Longevity Of Some Brands

The first drugs expected to face US Medicare drug price negotiations, according to a new analysis, will have had an average commercial life span of 15 years.

Medicare Reimbursement

Investors Take Flight After Bluebird Bio’s Sickle Cell Delay

Bluebird’s first two gene therapies are on the market, but a new delay to its biggest hope, the sickle cell disease candidate lovo-cell, has spooked investors.

Blood & Coagulation Disorders Gene Therapy

Pipeline Watch - ADD Meeting Dominates Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Research & Development

Set Alert for Research & Development

Latest From Research & Development

ThirtyFiveBio Makes Its Debut With First-In-Class GPR35 Antagonist Approach

Emerging Company Profile: Backed by $20m in seed funding, the UK firm is going against the grain by antagonizing, instead of agonizing, G protein-coupled receptor 35 with an eye to treating colorectal cancer and other gastrointestinal conditions.

Emerging Company Profile Companies

Investors Take Flight After Bluebird Bio’s Sickle Cell Delay

Bluebird’s first two gene therapies are on the market, but a new delay to its biggest hope, the sickle cell disease candidate lovo-cell, has spooked investors.

Blood & Coagulation Disorders Gene Therapy

Roche Continues To Cast Its Collaborations Net Wide

The Swiss major gets around 3,000 proposals per year and has assembled a 120-strong team to sift through them and access the best science out there. Global head of pharma partnering James Sabry tells Scrip what Roche is looking for in a partner.

Deals Business Strategies
See All
UsernamePublicRestriction

Register